Hepatic artery infusion chemotherapy (HAIC) plus sintilimab and bevacizumab biosimilar (IBI305) in initial unresectable hepatocellular carcinoma (HCC): A retrospective study. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback